Recombinant Biotechnology and Immunotherapy Centre
The project focuses upon the development of recombinant high-affinity ligands, recombinant proteins and genetic DNA/RNA vaccines with corpuscular carriers and molecular adjuvants, a new biotechnological trend in the development of recombinant vaccines, highly selective immunotherapeutics, diagnostics, and theranostics. The success of proposed multidisciplinary research will be based on the collaboration of four renowned teams with a high quality of staffing and infrastructure. These teams have been engaged in a long-standing cooperation, as documented by shared projects, publications, and patents.
OP – EU Operational Programme
Jan 1, 2018
Dec 31, 2022
77,301 thou. CZK